#### AUG 2 2 2005

#### 510(k) Summary

Introduction

According to the requirements of 21 CFR 807.92, the following information

provides sufficient detail to understand the basis for a determination of

substantial equivalence

Submitter's name, address, and contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

317-521-3831

Contact Person: Corina Harper

Date Prepared: July 22, 2005

Device name

Proprietary name: Iron Standard

Common name: Calibrator

Classification name: Calibrator, Secondary, Class II

Predicate device

The Iron Standard is substantially equivalent to the currently marketed

Elecsys® C-Peptide Calset (K033873).

Device description

The Iron Standard is a single-level product consisting of a gravimetrically prepared aqueous solution of Ferrous Ammonium Sulfate Hexahydrate.

Intended use

Iron Standard is for use in the calibration of quantitative Unsaturated Iron Binding Capacity (UIBC) assays on Roche clinical chemistry analyzers.

Continued on next page

### 510(k) Summary, Continued

Substantial equivalence: Similarities

The Iron Standard is substantially equivalent to the currently marketed Elecsys® C-Peptide Calset (K033873). The below tables compare Iron Standard with the predicate device, Elecsys® C-Peptide Calset.

Characteristic	Iron Standard	Predicate Device Elecsys® C-Peptide Calset (K033873)
Intended Use	For use in the calibration of quantitative Unsaturated Iron Binding Capacity (UIBC) assays on Roche clinical chemistry analyzers.	For calibrating the quantitative Elecsys® C-Peptide assay on the Elecsys® immunoassay systems.
Levels	One	Two

Continued on next page

## 510(k) Summary, Continued

Substantial equivalence: Differences

The below tables compare Iron Standard with the predicate device, Elecsys® C-Peptide Calset.

Characteristic	Iron Standard	Predicate Device Elecsys® C-Peptide Calset (K033873)
Format	Aqueous solution	Lyophilized
Handling	Ready to use	Add exactly 1.0 ml
		distilled water and
		allow to stand closed
		for 15 minutes to
		reconstitute. Mix
		carefully, avoiding the
		formation of foam.
Stability	Unopened:	Unopened:
	• Store at 15-25°C	• Store at 2-8°C until
	until expiration date	expiration date
	After opening:	Reconstituted:
	• 15-25°C: until	• -20°C: 1 month
	expiration date	(freeze only
		once)
		On the analyzers at
		20-25°C: use
		only once
Matrix	Gravimetrically	Equine serum with
	prepared aqueous	added synthetic human
	solution of Ferrous	C-Peptide.
	Ammonium Sulfate	
	Hexahydrate.	





Food and Drug Administration 2098 Gaither Road Rockville MD 20850

AUG 2 2 2005

Ms. Corina Harper, RAC Regulatory Affairs Consultant Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

Re:

k052002

Trade/Device Name: Iron Standard Regulation Number: 21 CFR 862.1150

Regulation Name: Calibrator Regulatory Class: Class II

Product Code: JIT Dated: July 22, 2005 Received: July 25, 2005

#### Dear Ms. Harper:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Carol C. Benson, M.A.

Acting Director

Division of Chemistry and Toxicology

Office of In Vitro Diagnostic Device

Carol C. Benson

**Evaluation and Safety** 

Center for Devices and

Radiological Health

Enclosure

# Indications for Use

510(k) Number (if known):	K052007	-	
Device Name:			
Iron Standard			
Indications For Use:			
Iron Standard is for use in the ca (UIBC) assays on Roche clinical		e Unsaturated Iron Binding Capacity	7
Prescription Use XXXX (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)	
(PLEASE DO NOT WRITE NEEDED)	BELOW THIS LINE-	CONTINUE ON ANOTHER PAGE	IF
Concurrence of CI	Division Sign-Off	Diagnostic Devices (OIVD)	_
Roche Diagnostics Confidential	Office of In Vitro I Evaluation and Saf 510(k) 052	ety	